Israel's Medical Cannabis Program Grew 4,400% in 13 Years
Israel's medical cannabis program expanded from about 3,100 active licenses in 2011 to over 140,000 by 2024, driven by regulatory reforms that broadened access, before declining 7.5% after a new HMO-led prescribing reform.
Quick Facts
What This Study Found
Active medical cannabis licenses in Israel grew by over 4,400% from 2011 to 2024. The 2024 reform transferring prescribing authority to HMOs was followed by a 7.5% decline in licenses. Chronic non-cancer pain remained the top indication (63%), with PTSD growing from 9% to 17%. Over 94% of patients used flower-based products by 2025.
Key Numbers
Licenses grew from 3,097 (2011) to 140,483 (January 2024), then declined to 129,900 by March 2025. Chronic pain: 63% of licenses. PTSD grew from 9% to 17%. Flower products: over 94% of usage. Monthly doses of 50g rose 108%, 60g rose 117%. Estimated annual market: $252-684 million at peak.
How They Did This
Longitudinal review and secondary analysis of monthly Israeli Medical Cannabis Unit reports from 2011 to 2025, mapping regulatory milestones to shifts in patient numbers, indications, dosages, product types, and prescribing patterns.
Why This Research Matters
Israel has one of the world's most established and data-rich medical cannabis programs. Understanding how its regulatory changes affected patient access provides lessons for other countries developing their own frameworks.
The Bigger Picture
Israel's experience shows that broadening access through regulatory reform can dramatically increase medical cannabis use, but shifting oversight to managed care organizations may introduce new gatekeeping that reduces access.
What This Study Doesn't Tell Us
Single-country analysis with a unique healthcare system. Post-2024 data gaps make it difficult to fully explain the license decline. Market value estimates are approximate.
Questions This Raises
- ?Will the HMO-led model continue to reduce access, or will it stabilize?
- ?How do patient outcomes compare across the different regulatory periods?
Trust & Context
- Key Stat:
- 4,400% growth in active licenses from 2011 to 2024
- Evidence Grade:
- Moderate: comprehensive longitudinal analysis of government data, but limited to administrative records without patient outcomes
- Study Age:
- Published in 2025 covering 2011-2025
- Original Title:
- Medical cannabis in Israel: a comprehensive review of trends and regulations, 2011-2025.
- Published In:
- Journal of cannabis research, 7(1), 90 (2025)
- Authors:
- Aviram, Joshua(2)
- Database ID:
- RTHC-05979
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why did licenses decline after 2024?
The 2024 reform transferred prescribing authority from specialist physicians to Health Maintenance Organizations (HMOs). The author suggests stricter HMO gatekeeping and transition friction may explain the decline, though data gaps make this difficult to confirm.
What conditions qualify for medical cannabis in Israel?
Chronic non-cancer pain is the most common (63% of licenses), followed by PTSD (17%). The range of approved indications expanded over time as the program evolved.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-05979APA
Aviram, Joshua. (2025). Medical cannabis in Israel: a comprehensive review of trends and regulations, 2011-2025.. Journal of cannabis research, 7(1), 90. https://doi.org/10.1186/s42238-025-00344-1
MLA
Aviram, Joshua. "Medical cannabis in Israel: a comprehensive review of trends and regulations, 2011-2025.." Journal of cannabis research, 2025. https://doi.org/10.1186/s42238-025-00344-1
RethinkTHC
RethinkTHC Research Database. "Medical cannabis in Israel: a comprehensive review of trends..." RTHC-05979. Retrieved from https://rethinkthc.com/research/aviram-2025-medical-cannabis-in-israel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.